Previous 10 | Next 10 |
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2023, on Thursday, May 11, 2023, after the market close. The Company will also post its first quarter Letter to Stockholders to th...
Harrow Health, Inc. (NASDAQ: HROW) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.72% on the day to $24.21. Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical co...
2023-04-04 08:47:51 ET Summary Harrow Health began commercial operations in 2014 with no products or customers, and today is the largest U.S. ophthalmic focused pharmacy. Harrow entered an opaque market filled with middle men and dissatisfied ophthalmologists. Harrow understands t...
B. Riley Leads Financing to Support Harrow Health Acquisition PR Newswire LOS ANGELES , March 28, 2023 /PRNewswire/ -- B. Riley Financial, Inc. (NASDAQ: RILY) ("B. Riley"), a diversified financial services platform, today announced that certain of its affiliates ...
2023-03-28 10:30:18 ET Harrow Health ( NASDAQ: HROW ) has agreed on $100M secured credit financing with funds managed by the investment manager Oaktree Capital Management. The interest-only credit facility carries an interest rate equal to the 3-month secured overnight fin...
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it has entered into a $100 million secured credit financing agreement with funds managed by Oaktree Capital Management, L.P. (“Oaktree”). The interest-only secured credit facility carries an i...
2023-03-23 20:58:06 ET Harrow Health, Inc. (HROW) Q4 2022 Earnings Conference Call March 23, 2023, 4:45 PM ET Company Participants Jamie Webb - Director, Communications and IR Mark Baum - Chief Executive Officer Andrew Boll - Chief Financial Officer Confere...
2023-03-23 17:01:12 ET Gainers: Pyxis Oncology ( PYXS ) +15% . CRISPR Therapeutics ( CRSP ) +11% . ADMA Biologics ( ADMA ) +6% . Harrow Health ( HROW ) +4% . Solid Power ( SLDP ) +5% . Losers: Scholastic ( SCHL ) -1...
2023-03-23 16:09:54 ET Harrow Health press release ( NASDAQ: HROW ): Q4 Non-GAAP EPS of $0.07. Revenue of $20.3M (+0.5% Y/Y) misses by $1.43M . For further details see: Harrow Health Non-GAAP EPS of $0.07, revenue of $20.3M misses by $1.43M
2022 and Recent Highlights: Full-year 2022 revenues of $88.6 million, up 22% over full-year 2021 revenues of $72.5 million Sold all non-ophthalmology assets, making Harrow a pure-play ophthalmic pharmaceutical company FDA approval of IHEEZO™ topical ocular anesthetic CMS ...
News, Short Squeeze, Breakout and More Instantly...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of Retina Specialists (ASRS) Annual Meeting, taking place in Stockholm, Sweden, from July 17-20, 2024. The ASRS Annual Meeting brings tog...
Contract Enhances Purchasing Power for 340B Prime Vendor Program (PVP) Participants; Aligns with Harrow’s Mission to Make Its Products Accessible and Affordable Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, ...